Shahzad Malik has a strong background in science, clinical medicine, and international finance. He gained an MA in Physiological Sciences from Oxford University and an MD from Cambridge University, after which he specialised in interventional cardiology while also pursuing clinical and fundamental scientific research in heart muscle disorders. Shahzad has been actively involved with 21 portfolio Companies in Europe and the USA in all sectors of Life Sciences, including Algeta, Respivert, Biocartis and PowderMed. Shahzad currently serves on the Board of several portfolio Companies, including Acutus, Agenus and Versartis.